OTCMKTS:VLRXQ Valeritas (VLRXQ) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free VLRXQ Stock Alerts $0.02 0.00 (0.00%) (As of 07/1/2020) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0252-Week Range$0.01▼$4.28VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Valeritas alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Valeritas Stock (OTCMKTS:VLRXQ)Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.Read More VLRXQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VLRXQ Stock News HeadlinesJune 20, 2023 | investing.comValeritas Holdings Inc (VLRXQ)October 13, 2022 | finance.yahoo.comWearable Injectors Market sales are expected to reach US$ 17.6 Bn by 2031 – Persistence Market Research - Yahoo FinanceMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).October 13, 2022 | benzinga.comWearable Injectors Market sales are expected to reach US$ 17.6 Bn by 2031 – Persistence Market Research - BenzingaSeptember 23, 2022 | finance.yahoo.comWearable Injectors Market Size to Hit $13485.22 Million by 2028 | Wearable Injectors industry Share to Rise at 16.90% CAGR during 2022 - 2028, Says Facts & Factors - Yahoo FinanceSeptember 23, 2022 | globenewswire.comWearable Injectors Market Size to Hit $13485.22 Million by 2028 - GlobeNewswireSeptember 14, 2022 | benzinga.comInsulin Pump Market to hit US$ 18.05 Billion by 2030 | Exclusive Report by Growth Plus Reports - BenzingaAugust 23, 2022 | finance.yahoo.comGlobal Insulin Patch Pumps Market Report 2022: Market is Expected to Reach $1.63 Billion in 2026 at a CAGR of 8.58% - Long-term Forecast to 2031 - Yahoo FinanceMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).August 22, 2022 | globenewswire.comGlobal Insulin Patch Pumps Market Report 2022: Market is Expected to Reach $1.63 Billion in 2026 at a CAGR of 8.58% - Long-term Forecast to 2031 - GlobeNewswireAugust 19, 2022 | finance.yahoo.comGlobal Insulin Patch Pumps Market Report 2022-2026 & 2031 - Integration with Smartphones and Enabling Automation Gaining Traction - Yahoo FinanceJuly 26, 2022 | businesswire.comWearable Injectors Global Market Report 2022: Market is Expected to Grow to $11.29 Billion in 2026 at a CAGR of 12% - Long-term Forecast to 2031 - ResearchAndMarkets.com - Business WireJuly 14, 2022 | benzinga.comGlobal Wearable Injectors Market (2022 to 2028) - Size, Share & Industry Trends Analysis Report - BenzingaJuly 11, 2022 | benzinga.comInsights on the Wearable Injectors Global Market to 2028 - Rising Consumer Preference for Home Care Solutions is Driving Growth - BenzingaJuly 6, 2022 | businesswire.comGlobal Insulin Pens, Syringes, Pumps And Injectors Market Report 2022: Increase in the Prevalence of Diabetes Globally is Driving Growth - ResearchAndMarkets.com - Business WireJuly 4, 2022 | finance.yahoo.comA $18.8 Billion Global Opportunity for Self-care Medical Devices by 2026 - New Research from StrategyR - Yahoo FinanceJune 29, 2022 | globenewswire.comInsights on the Ultra large Volume Wearable Injectors Global Market to 2027 - Featuring Amgen, BASF and Insulet Among Others - GlobeNewswireJune 27, 2022 | finance.yahoo.comInsights on the Ultra large Volume Wearable Injectors Global Market to 2027 - Featuring Amgen, BASF and Insulet Among Others - Yahoo FinanceJune 18, 2022 | gurufocus.comApexigen Appoints William Duke as Chief Financial Officer - GuruFocus.comJune 15, 2022 | benzinga.comDiabetes Devices Market Value to Reach $54.16 Billion by 2030: Grand View Research, Inc. - Benzinga - BenzingaJune 8, 2022 | globenewswire.comApexigen Appoints William Duke as Chief Financial Officer - GlobeNewswireJune 3, 2022 | businesswire.comMicroneedle Drug Delivery Systems Global Market Research Report 2022 - ResearchAndMarkets.com - Business WireMay 24, 2022 | finance.yahoo.comMicroneedle Drug Delivery Systems Global Market Report 2022 - Yahoo FinanceMay 24, 2022 | finance.yahoo.comWearable Injectors Global Market Report 2022 - Yahoo FinanceMay 24, 2022 | globenewswire.comWearable Injectors Global Market Report 2022 - GlobeNewswireMay 23, 2022 | globenewswire.comAutoinjectors Market to reach 238.7 billion in 2030 with a CAGR of around 17.9% asserts Strategic Market Research. Lets make you acquainted with some of the most crucial statistics related to this market. - GlobeNewswireApril 6, 2022 | finance.yahoo.comMicro-Needle Patch Market to Reach Value of USD 1,034.5 Million in 2028 | Increasing Government Funding and Rise in the Diabetic Population All Over the World are Key Factors Driving Industry Demand, Says Emergen Research - Yahoo FinanceSee More Headlines Receive VLRXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valeritas and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2019Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:VLRXQ CUSIPN/A CIK1619250 Webwww.valeritas.com Phone908-927-9920Fax908-927-9927Employees125Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John E. Timberlake (Age 54)Pres, CEO & Director Mr. Erick J. Lucera CPA (Age 51)CFA, CFO & Sec. Mr. Geoffrey H. Jenkins (Age 67)Exec. VP of Manufacturing, Operations and R&D Dr. Matthew H. Nguyen (Age 49)Chief Commercial Officer Mr. Scott A. HuieVP of Regulatory Affairs/Quality Assurance and ComplianceKey CompetitorsAdynxxOTCMKTS:ADYXCalmare TherapeuticsOTCMKTS:CTTCDex LiquidatingOTCMKTS:DXTRQEndologixOTCMKTS:ELGXQLifePointOTCMKTS:LFPIView All Competitors VLRXQ Stock Analysis - Frequently Asked Questions How have VLRXQ shares performed in 2024? Valeritas' stock was trading at $0.02 at the beginning of the year. Since then, VLRXQ stock has increased by 0.0% and is now trading at $0.02. View the best growth stocks for 2024 here. How were Valeritas' earnings last quarter? Valeritas Holdings, Inc. (OTCMKTS:VLRXQ) issued its earnings results on Tuesday, November, 12th. The company reported ($1.91) EPS for the quarter, topping analysts' consensus estimates of ($2.52) by $0.61. The business earned $8.46 million during the quarter. How do I buy shares of Valeritas? Shares of VLRXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VLRXQ) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsYour bank is lying to you.MyBankTrackerTrump just won 2024Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valeritas Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.